Adenosine Triphosphate (ATP) News and Research

RSS

New compound may halt drug-resistant lung cancer

The ability to make, test, and map the atomic structure of new anti-cancer agents has enabled a team of Dana-Farber Cancer Institute scientists to discover a compound capable of halting a common type of drug-resistant lung cancer.

24 Dec 2009

Researchers discover how protein can be controlled and under what circumstances it can go awry

A team of researchers studying the protein that, when defective or absent, causes cystic fibrosis (CF) has made an important discovery about how that protein is normally controlled and under what circumstances it might go awry.

18 Dec 2009

AstraZeneca's CRESTOR receives favorable vote from FDA Advisory Committee

The U.S. Food and Drug Administration (FDA) Endocrinologic and Metabolic Drugs Advisory Committee (EMDAC) today voted 12 yes, 4 no, and 1 abstention that AstraZeneca has established sufficient benefit to offset the observed risks to support the use of CRESTOR®

16 Dec 2009

Scientists present new research on adipocyte regulation

The ninth Colloque Médecine et Recherche of la Fondation Ipsen devoted to Endocrinology, held in Paris on December 4, 2009, has reviewed the recent progress in understanding the regulation of fat storage in the body and the consequences of the breakdown of this regulation.

14 Dec 2009

Discovery of new compounds may dispel cravings of methamphetamine and cocaine addiction

Sarah Steele and Langtian "Ren" Yuan were both self-admittedly inexperienced Duke freshmen in the spring of 2006. But then they followed helpful directions of an assistant chemistry professor, added their own patience and ingenuity, and ended up identifying compounds that might allay the powerful cravings of methamphetamine and cocaine addiction.

9 Dec 2009

Gamma Labs sponsors the Charles Evans PCF Pro/Am Tour

On December 1, 2009 at the annual Prostate Cancer Foundation Annual Dinner, the organization acknowledged its sponsors and provided insight of the year’s events and milestones. Gamma Labs, a leading nutritional supplement company, was recognized as one of the organization’s sponsors. Gamma Labs is pleased to announce today plans to continue support of this organization. Gamma Labs serves as a sponsor for the Charles Evans PCF Pro/Am Tour, an annual event that benefits the Prostate Cancer Foundation.

5 Dec 2009

Study reveals current cleaning methods can do more harm than good to school environments

A study performed by Coverall Health-Based Cleaning System(SM), a leading franchisor of commercial cleaning businesses, revealed that methods used by outside cleaning contractors could actually do more harm than good to indoor environments.

2 Dec 2009

Researchers uncover atomic-level action of ring-shaped protein motors

The atomic-level action of a remarkable class of ring-shaped protein motors has been uncovered by researchers with the Lawrence Berkeley National Laboratory (Berkeley Lab) using a state-of-the-art protein crystallography beamline at the Advanced Light Source (ALS).

25 Nov 2009

NovaBay Pharmaceuticals' Aganocide compounds demonstrate potent antifungal activity against onychomycosis

NovaBay Pharmaceuticals, Inc. today announced that its Aganocide® compounds demonstrate potent antifungal activity in an established pre-clinical infected nail model of onychomycosis. The study data will be presented tomorrow at the 47th Annual Meeting of the Infectious Diseases Society of America (IDSA) in Philadelphia.

31 Oct 2009

Starting Grant from ERC to LMU junior researchers

Two junior researchers from Ludwig-Maximilians-Universit-t (LMU) in Munich shall each receive a Starting Grant from the European Research Council (ERC). Professor Jens Michaelis, Department of Chemistry and Biochemistry, and Privatdozent Dr. David V-hringer, Institute of Immunology, shall receive grants amounting to 1.4 and 1.7 million Euros over five years. With its Starting Grant, the ERC supports highly creative researchers in order to encourage pioneering frontier research.

27 Oct 2009

Innovative approach to build a new drug to treat a number of CNS diseases

Working like an architect, Prof. Hagit Eldar-Finkelman of Tel Aviv University's Sackler School of Medicine is "building" a new drug, L803-MTS, to treat a number of central nervous system (CNS) diseases like Alzheimer's. In pre-clinical studies, it also shows promise against Parkinson's, Huntington's and diabetes.

27 Oct 2009

LIVALO statin effective than simvastatin in reducing lipid levels

New Phase III data published today in "Current Medical Research and Opinion" highlight that the recommended starting dose of 2 mg of LIVALO (pitavastatin), a novel synthetic statin, was statistically superior to simvastatin at a dose of 20 mg over 12 weeks in reducing low-density lipoprotein cholesterol

22 Oct 2009

NHGRI grants BioNanomatrix $833,490 for commercial development of its NanoAnalyzer system

BioNanomatrix, Inc., a developer of breakthrough single-molecule genomic analysis technology, today announced receipt of two new supplemental grants totaling $833,490 from the National Human Genome Research Institute (NHGRI) of the U.S. National Institutes of Health (NIH). The funding is intended to support further commercial development of BioNanomatrix's nanoscale whole genome imaging and analysis platform.

15 Oct 2009

Researchers discover that ATP transmits temperature information to afferent sensory neurons

A Japanese research group led by Prof. Makoto Tominaga and Dr. Sravan Mandadi (National Institute for Physiological Sciences: NIPS) found that ATP plays a key role in transmitting temperature information from skin keratinocytes to afferent sensory neurons. Their findings were presented in the Pflugers Archiv European Journal of Physiology published on October 2009.

9 Oct 2009

Calcium to cure cardiovascular problems

Calcium is crucial for heart regeneration by cardiac stem cells following cardiovascular problems say scientists in an article to be published in the journal Circulation Research this 9th of October.

9 Oct 2009

Pfizer to commence Phase 3 trial of oral c-Met and ALK inhibitor

Pfizer Oncology announced today that it will initiate a global, Phase 3 clinical trial of its investigational oral c-Met and ALK inhibitor, PF-02341066, versus standard of care chemotherapy in patients with advanced non-small cell lung cancer (NSCLC) carrying the ALK (anaplastic lymphoma kinases) fusion gene, who have progressed on one prior treatment with a platinum-based chemotherapy.

26 Sep 2009

Research study links high-fructose diet to increased blood pressure in men

A high-fructose diet raises blood pressure in men, while a drug used to treat gout seems to protect against the blood pressure increase, according to research reported at the American Heart Association's 63rd High Blood Pressure Research Conference.

24 Sep 2009

Pfizer Oncology to present early-stage research of investigational agents for cancer treatment

Pfizer Oncology will present data from across its portfolio, including results from long-term follow-up of Aromasin® (exemestane tablets) in a study of early breast cancer, updated study results from a Phase 3 study of Sutent® (sunitinib malate) in pancreatic neuroendocrine tumors (NET), and early-stage research of investigational agents PF-02341066 and figitumumab (CP-751,871) in patients with non-small cell lung cancer (NSCLC).

19 Sep 2009

Fill-to-light external tray from TCGRx

TCGRx (TCG), a leader in pharmacy automation and workflow solutions, announced today that the company is launching the Safe Tray, a fill-to-light external tray, a revolutionary safety product to aide in oral solid pouch packaging with TCG’s Automatic Tablet Packager (ATP-Series).

15 Sep 2009

Newly discovered molecular circuit helps maintain proper body metabolism

Researchers at the University of Pennsylvania School of Medicine have discovered a molecular circuit involving heme that helps maintain proper metabolism in the body, providing new insights into metabolic disorders such as obesity and diabetes.

14 Sep 2009